Long-Term Effects of Varying Alcohol Dosing in Percutaneous Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Randomized Study With a Follow-up up to 11 Years

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F11%3A7161" target="_blank" >RIV/00064203:_____/11:7161 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/11:7161

Výsledek na webu

<a href="http://www.ncbi.nlm.nih.gov/pubmed/22000583" target="_blank" >http://www.ncbi.nlm.nih.gov/pubmed/22000583</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Long-Term Effects of Varying Alcohol Dosing in Percutaneous Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Randomized Study With a Follow-up up to 11 Years

Popis výsledku v původním jazyce

Background: Highly symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) are candidates for alcohol septal ablation (ASA). We wanted to determine long-term (> 60 months) clinical and echocardiographic outcomes of patients treated with low (1-2 mL) or high (> 2 mL) doses of alcohol. Methods: Seventy-six patients were randomized into 2 arms in a 1: 1 ratio, and subsequently were treated by ASA with a low (1-2 mL) or high (> 2 mL) dose of alcohol. Clinical and echocardiographic examinations were performed at baseline, 1 year after the procedure, and at the end of follow-up (at least 60 months after ASA). Results: Both groups of patients matched in all baseline clinical and echocardiographic data. In a total of 76 patients, 86 septal branches were ablated in 80 ASA procedures (2 repeat procedures in each group). There were no differences in postprocedural complications. Seven patients (4 vs 3 patients; not significant) died during follow-up (60-138 months; median 85 month

Název v anglickém jazyce

Long-Term Effects of Varying Alcohol Dosing in Percutaneous Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Randomized Study With a Follow-up up to 11 Years

Popis výsledku anglicky

Background: Highly symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) are candidates for alcohol septal ablation (ASA). We wanted to determine long-term (> 60 months) clinical and echocardiographic outcomes of patients treated with low (1-2 mL) or high (> 2 mL) doses of alcohol. Methods: Seventy-six patients were randomized into 2 arms in a 1: 1 ratio, and subsequently were treated by ASA with a low (1-2 mL) or high (> 2 mL) dose of alcohol. Clinical and echocardiographic examinations were performed at baseline, 1 year after the procedure, and at the end of follow-up (at least 60 months after ASA). Results: Both groups of patients matched in all baseline clinical and echocardiographic data. In a total of 76 patients, 86 septal branches were ablated in 80 ASA procedures (2 repeat procedures in each group). There were no differences in postprocedural complications. Seven patients (4 vs 3 patients; not significant) died during follow-up (60-138 months; median 85 month

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT11401" target="_blank" >NT11401: Význam spánkové apnoe v patofyziologii hypertrofické kardiomyopatie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Canadian Journal of Cardiology

ISSN

0828-282X

e-ISSN

—

Svazek periodika

27

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

CA - Kanada

Počet stran výsledku

5

Strana od-do

763-767

Kód UT WoS článku

000297990600020

EID výsledku v databázi Scopus

—